Targets › FBIAB
1 program from 1 company in 1 trial: 1 Phase 4; Infectious disease; next expected readout Dec 2027.
Open in Phaseline: the race on FBIAB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Asan Medical Center | Pretomanid Mycobacterial bioenergetics inhibitor (prodrug activated by Mycobacterium tuberculosis) | FBIAB | Phase 4 | Multidrug- and Rifampicin-resistant Tuberculosis | Dec 2027 |
Multidrug- and Rifampicin-resistant Tuberculosis (1)
small molecule (1)
Asan Medical Center (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.